Literature DB >> 3129505

Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression.

D A Wall1, S D Hamberg, D S Reynolds, S J Burakoff, A K Abbas, J L Ferrara.   

Abstract

Irradiated CBA/J mice transplanted with H-2 compatible, minor histocompatibility disparate B10.BR bone marrow develop graft-versus-host disease (GVHD) if mature T lymphocytes are added to the marrow inoculum. In the setting of mild GVHD (receiving 10(4) or 10(5) T cells), by phenotypic analysis, lymphoid reconstitution occurs normally within 4 to 6 wk but there is a profound deficiency in the ability of splenic lymphocytes to respond to polyclonal activators such as LPS and Con A. This unresponsiveness is attributable to active suppression mediated by cells that express Thy-1 and can be removed with leucine methyl ester treatment. Thus, splenocytes from mice with GVHD suppress responses of normal T and B lymphocytes. Moreover, depletion of these suppressor cells restores normal function to splenocytes from mice with GVHD, and B cells isolated from these mice respond normally to T-dependent and -independent stimulation. Finally, IFN-gamma plays an important role in this suppression, because a neutralizing anti-IFN-gamma mAb significantly removes suppression of normal cells and restores functional responses of lymphocytes from mice with GVHD. These results provide insights into the mechanisms of immunodeficiency associated with GVHD, and suggest novel strategies for possible therapies for this disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.

Authors:  M B Baker; R L Riley; E R Podack; R B Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Graft-versus-host reaction enhanced by ultraviolet radiation.

Authors:  T Kitajima; S Imamura
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

3.  Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells.

Authors:  David Caretto; Shoshana D Katzman; Alejandro V Villarino; Eugenio Gallo; Abul K Abbas
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

4.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

5.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.

Authors:  Vu H Nguyen; Sumana Shashidhar; Daisy S Chang; Lena Ho; Neeraja Kambham; Michael Bachmann; Janice M Brown; Robert S Negrin
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

7.  The engraftment of transplanted bone marrow-derived cells into the inner ear.

Authors:  Yorihisa Orita; Hidetsugu Tsujigiwa; Kazunori Nishizaki; Takanori Teshima; Junko Yoshinobu; Saeko Orita; Ayako Takeuchi; Yasushi Takeda; Hitoshi Nagatsuka; Noriyuki Nagai
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-10       Impact factor: 2.503

Review 8.  Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.

Authors:  Ying Lu; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2009-11       Impact factor: 5.742

Review 9.  Graft-versus-host disease and the Th1/Th2 paradigm.

Authors:  W Krenger; J L Ferrara
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

10.  Lymphocytes with a CD4+ CD8- CD3- phenotype are effectors of experimental cutaneous graft-versus-host disease.

Authors:  H Sakamoto; J Michaelson; W K Jones; A K Bhan; S Abhyankar; M Silverstein; D E Golan; S J Burakoff; J L Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.